Palliative Thoracic ImmunoRT
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
Lung Cancer, Nonsmall Cell|Lung Cancer
RADIATION: Radiation combined with immunotherapy
Rate of Radiation related toxicities, rates of radiation-related toxicities in the combination of immunotherapy and palliative thoracic radiotherapy using CTCAE v5.0 grading, up to 24 months|Patient Report Outcome, FACT-E, up to 12 months|Patient experience and anxiety related to Quality of Life, EQ-5D, up to 12 months
Rate of Survival, 1 year|Rate of Survival, 2 year|Rate of Disease Recurrence, Patients will be followed for up to two years following the completion of their radiotherapy. They will undergo CT surveillance imaging as standard by routine immunotherapy protocol with a minimum of 3 scans at the 3, 6 and 12 month mark. Local and distant recurrence will be determined primarily by CTCAE with CT scans as per ir-RECIST v1.0 criteria., 3, 6, 12 months
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.